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Abstract
Parathyroid hormone (PTH) is currently the only approved anabolic agent for osteoporosis
pharmacotherapy in the USA. However, the molecular and cellular mechanisms underlying which
intermittent PTH stimulates bone formation are not fully established.
Activating transcription factor 4 (ATF4) was recently identified to be a downstream target of PTH
signaling in osteoblasts and FGF2 is able to rapidly increase ATF4 mRNA and protein expression
in osteoblasts. Furthermore, ATF4 expression is markedly reduced in Fgf2−/− osteoblasts. In
addition, FGF2 is required for the anabolic action of PTH on bone formation. Therefore, we
hypothesize that the impaired anabolic effect of PTH in Fgf2−/− mice is partially due to reduced
ATF4 expression. To test this hypothesis, we examined the ability of PTH to increase ATF4
expression in vitro and in vivo. In vitro data showed that PTH induced a significant increase in
ATF4 mRNA expression as early as 15 min in Fgf2+/+ primary bone marrow stromal cells
(BMSCs) but not in Fgf2−/− BMSCs. In vivo data showed that treatment with PTH (1–34) (40 μg/
kg/d) treatment for 2 weeks in 21–23 months female mice increased lumbar vertebrae bone
mineral density in Fgf2+/+ (13.8% increase). In contrast there was a 2.1% decrease in Fgf2−/−
mice. Interestingly, basal ATF4 mRNA expression in tibiae was significantly lower in Fgf2−/−
mice (46% decrease) compared to Fgf2+/+ mice. PTH treatment increased ATF4 mRNA by 97%
(p< 0.05) in Fgf2+/+ compared to 8% (p = 0.57) in Fgf2−/− mice. Immunohistochemistry of
vertebrae showed less ATF4 staining in Fgf2−/− tissue, and treatment with PTH increased ATF4
staining in Fgf2+/+ but the increase was attenuated in Fgf2−/− tissue.
In summary, reduced ATF4 expression may result in decreased osteoblast differentiation, and
possibly contribute to the impaired stimulation of PTH on bone formation in Fgf2−/− mice.
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1. Introduction
Osteoporotic fracture is estimated to occur every 3 s worldwide [1]. Osteoporosis is a
disease characterized by low bone mass and deterioration in the microarchitecture of bone
tissue [2]. Currently, the only available anabolic agent in clinical use for the treatment of
osteoporosis in USA is PTH. Intermittent administration of PTH peptide 1–34 or full-length
protein PTH 1–84 increases bone formation in osteoporotic patients [3]. However, the
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molecular and cellular mechanisms underlying which intermittent PTH stimulates bone
formation are not fully established.
Our previous studies demonstrate that anabolic action of PTH on bone formation requires
FGF2. PTH increases FGF2 and FGF receptor mRNA expression in cultured osteoblasts [4].
Furthermore, PTH treatment increases serum FGF2 and increases bone formation markers in
osteoporotic patients [5]. However disruption of FGF2 gene in mice results in dramatic
reduction in bone formation [6], suggesting the importance of endogenous FGF2 in bone
formation. Moreover, in Fgf2−/− mice, PTH has impaired ability to stimulate bone formation
[7]. These studies indicate that FGF2 is required for PTH to stimulate bone formation.
Bone formation is mediated by osteoblasts. Osteoblast differentiation from bone marrow
stromal cell is governed by transcription factors, including Runx2 and ATF4 [8]. ATF4 is
critical for osteoblast terminal differentiation and for maintaining mature osteoblast function
including synthesizing collagen and osteocalcin [9]. Osteocalcin is one transcriptional target
of ATF4 in osteoblasts [9]. The requirement of ATF4 in osteoblast differentiation is
revealed by ATF4 knock out mice. Atf4−/− mice display a dramatic decrease in osteocalcin
expression together with severe reduction of bone mass and bone formation [9]. In contrast,
ATF4 overexpression increases osteocalcin expression in osteoblasts [10]. These studies
suggest that ATF4 is a transcriptional activator required for osteoblast terminal
differentiation and osteocalcin expression.
ATF4 has recently been identified as a novel downstream target gene of PTH signaling in
osteoblasts [11,12]. PTH induces ATF4 mRNA/protein expression and increases ATF4
transcriptional activity in MC3T3-E4 cells and in BMSCs [11]. But PTH could not induce
osteocalcin expression in ATF4 knockdown MC3T3-E4 cells or in Atf4−/− BMSCs [11].
Moreover, the anabolic actions of PTH in bone was severely impaired in Atf4−/− mice [12].
These results suggest that bone formation stimulated by PTH is in part mediated by ATF4.
We recently reported that ATF4 expression is regulated by FGF2 in osteoblasts. FGF2 is
able to rapidly increase ATF4 mRNA and protein expression in osteoblasts [13].
Furthermore, ATF4 expression is markedly reduced in Fgf2−/− osteoblasts [13]. Therefore,
we hypothesize that the impaired anabolic effect of PTH in Fgf2−/− mice is partially due to
reduced ATF4 expression. To test this hypothesis, we examined the ability of PTH to
increase ATF4 expression both in vitro and in vivo.
In this study, we provide evidence that PTH is not able to induce ATF4 mRNA expression
in the absence of FGF2 in BMSCs in vitro and PTH in vivo treatment increased ATF4
mRNA expression in tibia and ATF4 protein expression in vertebrae tissue is attenuated in
FGF2 knockout mice. These results suggest that the impaired bone response to PTH in
Fgf2−/− mice is in part due to reduced ATF4 expression.
2. Materials and methods
2.1. Animals
Fgf2 knockout mice were previously developed on a black swiss 129Sv background [14].
Mice used in this study were on a new mix genetic background of black swiss 129Sv/FVB/
N. Genotyping of mice was performed using primers as previously described [14,15]. Mice
were bred and housed in the transgenic facility in the center for laboratory animal care at the
University of Connecticut Health Center. Mice were sacrificed by CO2 narcosis and cervical
dislocation. The Animal Care and Use Committee of the University of Connecticut Health
Center approved all animal protocols.
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Littermates of male or female mice were utilized as indicated in the figure legends. For PTH
injection experiments, two independent studies were done using 17–19 month old mice (n =
3–4/group) or 21–23 month-old female mice (n = 2–3/group) that were weighed and injected
subcutaneously with vehicle (0.001 M HCl in PBS with 1 mg/ml BSA) (n = 2–3) or 40 μg/
kg human PTH (1–34) (Bachem, Torrence, CA, USA) 5×/week for 2 weeks. Two days after
the last injection of PTH, in vivo vertebral BMD and BMC were determined, and then the
third vertebrae were placed in 10% phosphate-buffered formalin for 48 h and subsequently
stored in 70% ethanol before immunohistochemistry staining. Left tibia were dissected and
cut off the epiphyses for RNA extraction.
2.2. Bone mineral density (BMD) and bone mineral content (BMC)
In vivo vertebral BMD and BMC were determined using dual energy X-ray absorptiometry
(DXA; PIXimus mouse 11 densitometer, GE Medical System, Madison WI).
2.3. RNA isolation and quantitative real-time PCR analysis
Total RNA was extracted from cells with TRIzol reagent (Invitrogen, CA, USA) according
to the manufacture's protocol. RNA (3 μg) was reverse transcribed using a commercial kit
(Clontech, CA, USA). Quantitative real-time PCR (qPCR) was carried out using the
QuantiTect™ SYBR Green PCR kit using a MyiQ™ instrument (Bio-Rad, Laboratories Inc.
Hercules, CA, USA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an
internal reference for each sample. Relative mRNA expression was calculated using a
formula reported previously [16]. The mouse specific primers are as follows: Gapdh, 5′-
CAG TGC CAG CCTCGT CCC GTA GA-3′ (forward), 5′-CTG CAA ATG GCA GCC
CTGGTG AC-3′ (reverse); osteocalcin, 5′-GAG GGC AAT AAG GTA GTG AAC
AGA-3′ (forward), 5′-AAG CCA TAC TGG TTT GAT AGC TCG-3′ (reverse); Type I
collagen (col1a1), 5′-GGT CCT CGT GGT GCT GCT-3′ (forward), 5′-ACC TTT GCC
CCC TTC TTT G-3′ (reverse); Atf4, 5′ –GAG CTT CCT GAA CAG CGA AGT G-3′
(forward), 5′ -TGG CCA CCT CCA GAT AGT CAT C-3′ (reverse).
2.4. Immunohistochemistry staining
For histological analysis, vertebrae samples incubated in 70% ethanol were decalcified in
20% EDTA in PBS for 7 days at room temperature and paraffin blocks were prepared by
standard procedures. Samples were then cut into 5 μm sections. Sections were
deparaffinized and stained with ATF4 antibody (1:50, Santa Cruz, CA, USA) using ABC
staining system (Santa Cruz, CA, USA) following the product protocol.
2.5. Bone marrow stromal cell cultures
For PTH in vitro treatment experiments, BMSC-isolation was described previously [13].
Briefly, femurs and tibiae from Fgf2+/+ and Fgf2−/− mice were dissected and both epiphyses
were removed, then bones were centrifuged briefly in eppendorf tubes to release bone
marrow cells. The marrow cells were plated at 10 × 106 cells/well in six-well plates in α -
MEM (Gibco-BRL, Grand Island, New York, USA) containing 10% fetal bovine serum
(FBS), penicillin (100 U/ml) and streptomycin (50 μg/ml). To study whether exogenous
PTH promoted ATF4 expression, the cells had half medium changed on day 3 and the entire
medium changed on day 6 with FBS-free α-MEM, with serum deprivation 14 h before
adding exogenous 1 nM PTH or vehicle for 15 min, 30 min, 1 h, 3 h, or 6 h. Then cells were
harvest for RNA extraction and gene analysis as describe above.
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Results were expressed as the means ± SEM. Differences between wild type vs knockout or
vehicle vs treatment were analyzed using a student's t-test, and differences were considered
significant at p < 0.05.
3. Results
3.1. PTH is not able to increase ATF4 mRNA expression in the absence of endogenous
FGF2 in BMSCs in vitro
The ability of PTH to increase ATF4 expression was first examined in BMSCs. As shown in
Fig. 1, ATF4 mRNA expression is significantly reduced in Fgf2−/− BMSCs compared to
Fgf2+/+ BMSCs at basal level. PTH treatment significantly increased ATF4 mRNA
expression in Fgf2+/+ BMSCs as early as 15 min. However, PTH was not able to increase
ATF4 mRNA expression in Fgf2−/− BMSCs at all the time points examined.
3.2. Anabolic action of PTH on bone formation is impaired in Fgf2−/− mice compared to
wild type littermates
We next assessed bone formation stimulated by PTH in 21– 23 month-old female mice on a
black swiss 129Sv/FVB/N genetic background. We observed that PTH treatment increased
lumbar vertebrae BMD in Fgf2+/+ mice with a 13.8% increase. In contrast there was a 2.1%
decrease in Fgf2−/− mice (Fig. 2A). PTH treatment increased lumbar vertebrae BMC with a
19.8% increase in Fgf2+/+ mice but there was a 9.9% decrease in Fgf2−/− mice (Fig. 2B).
We also examined genes that are important for osteoblasts differentiation using RNA
extracted from tibiae after PTH in vivo administration. For Col1a1 mRNA expression (Fig.
2C), PTH induced a 363% increase in Fgf2+/+ mice vs a 118% in Fgf2−/− mice. As shown in
(Fig. 2D), PTH induced a 221% increase in osteocalcin expression in Fgf2+/+ mice vs 173%
in Fgf2−/− mice. Also (Fig. 2E), PTH injection induced a 51% increase in Runx2 mRNA
expression in Fgf2+/+ mice vs 10% in Fgf2−/− mice. These data showed that increased gene
expression of osteocalcin, Col1a1 and Runx2 stimulated by PTH injection were attenuated
in Fgf2−/− mice compared to Fgf2+/+ mice. Impaired bone anabolic response to PTH was
also seen in 17–19 month-old female mice with 16.9% increase in vertebrae BMD in
Fgf2+/+ mice vs 6.2% increase in Fgf2−/− mice.
3.3. Increased ATF4 mRNA and protein expression by PTH injection is attenuated in
Fgf2−/− mice compared to wild type littermates
Since the anabolic action of PTH on bone formation requires ATF4, we investigated the
ability of PTH to increase ATF4 expression in vivo in 21–23 month old female Fgf2−/− mice
compared to wild type littermates. Interestingly, ATF4 mRNA expression in tibiae was
significantly lower in Fgf2−/− mice (a 46% decrease) compared to Fgf2+/+ mice. PTH
treatment increased ATF4 mRNA expression by 97% (p < 0.05) in Fgf2+/+ compared to 8%
(p = 0.57) in Fgf2−/− mice, as shown in Fig. 3A.
We further examined ATF4 protein in vivo expression by immunohistochemistry on lumbar
vertebrae after PTH injection. As shown in Fig. 3B, there was less ATF4 staining in Fgf2−/−
vertebrae tissue, particularly in osteoblast cells lining the bone surface (arrow) compared to
Fgf2+/+ tissue, and treatment with PTH increased ATF4 staining in Fgf2+/+ but the increase
was attenuated in Fgf2−/− tissue.
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In the present study, we found that PTH did not increase ATF4 mRNA expression in the
absence of endogenous FGF2 in BMSCs in vitro. Furthermore, increased ATF4 mRNA in
tibia and ATF4 protein expression in vertebrae tissue by PTH injection is attenuated in
Fgf2−/− mice compared to wild type littermates. Attenuated ATF4 expression may
contribute to the impaired anabolic actions of PTH on bone formation in Fgf2−/− mice.
The impaired bone anabolic response of PTH in Fgf2−/− mice on a new genetic background
of black swiss/129Sv/FVB/N is similar to the results reported in mice on a black swiss/
129Sv genetic background [7]. One also needs to note that the dose of PTH treatment in the
current study 40 μg/kg for 5×/week for 2 weeks was much lower that the dose used in our
previous studies (80 μg/kg once daily for 4 weeks or 160 μg/kg for 10 days). These data
further support that the anabolic bone response to PTH requires FGF2.
We previously reported that PTH treatment increased serum FGF2 and increased bone
formation markers in osteoporotic patients [5]. In cultured osteoblasts, PTH increased FGF2
and FGF receptor mRNA expression [4]. The increased bone formation stimulated by PTH
may be due to increased FGF2, since the ability of PTH to stimulate bone formation is
impaired in the absence of endogenous FGF2 [7]. FGF2 positively regulated osteoblast
differentiation and bone formation. Disruption of the Fgf2 gene resulted in significantly
decreased bone mass and bone formation as revealed by histomorphometry and micro-CT
[15,17]. Decreased osteoblast differentiation might be due to reduced expression of
transcription factors, since we found that reduced ATF4 expression in osteoblasts was
associated with reduced bone formation in Fgf2−/− mice [13]. Furthermore, exogenous
FGF2 was able to induce ATF4 expression [13]. These results suggest that ATF4 may be a
down stream target of FGF2 signaling in osteoblasts (Fig. 4).
ATF4 is a transcriptional activator for osteoblasts differentiation. Expression of the latest
marker of differentiated osteoblasts osteocalcin and synthesis of the major constituent of the
bone matrix type I collagen require ATF4 [9]. Atf4 deficient mice display reduced type I
collagen synthesis, decreased osteocalcin expression and low bone mass compared to wild
type [9]. Therefore, ATF4 is an essential regulator of osteoblast biology. Recent studies
demonstrated that ATF4 is critical in the anabolic actions of PTH in bone [11,12]. PTH
increased osteocalcin expression in Atf4−/− BMSCs was attenuated [12] and PTH stimulated
bone formation in Atf4 deficient mice was severely impaired [13]. Thus, PTH signaling in
bone is in part mediated by ATF4.
To our knowledge, this is the first report that the impaired bone anabolic response of PTH in
the absence of FGF2 is associated with attenuated ATF4 expression. The attenuated ATF4
expression may contribute to reduced osteoblast differentiation with decreased type I
collagen and osteocalcin expression and reduced bone formation (Fig. 4). Future studies will
address whether ATF4 over-expression is able to rescue the impaired anabolic actions of
PTH on bone formation in Fgf2 knockout mice.
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PTH is not able to increase ATF4 mRNA expression in the absence of endogenous FGF2 in
BMSCs in vitro. ATF4 mRNA expression is significantly reduced in Fgf2−/− BMSCs
compared to Fgf2+/+ BMSCs at basal level. PTH treatment significantly increased ATF4
mRNA expression in Fgf2+/+ BMSCs as early as 15 min. However, PTH does not increase
ATF4 mRNA expression in Fgf2−/− BMSCs at the time points examined. Freshly isolated
BMSCs from 3 months old male mice were cultured in αMEM with 10% FBS for 6 days,
serum deprived 14 h, then treated with 1 nM PTH or vehicle at the indicated times, followed
by total RNA extraction for gene analysis. Data are mean ± SEM for two to three
independent experiments.
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Anabolic action of PTH on bone formation is impaired in Fgf2−/− mice compared to wild
type littermates on a new mix genetic background of black swiss 129Sv/FVB/N. Increased
vertebral BMD (A) and BMC (B) by PTH injection is attenuated in Fgf2−/− mice. PTH
stimulation of genes important in osteoblast differentiation; type I collagen Col1a1 (C),
osteocalcin (D) and Runx2 (E) by PTH is attenuated in tibia of Fgf2−/− mice. 21–23 ms old
female mice were injected subcutaneously 5×/week for two weeks with either vehicle or
PTH (40 lg/kg BW) as described in materials and methods. Two days after the last injection,
BMD and BMC were determined and total RNA was extracted from whole tibia excluding
epiphyses for gene analysis by qPCR.
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Increased ATF4 mRNA and protein expression in vertebrae tissue by PTH injection is
attenuated in Fgf2−/− mice compared to wild type littermates. 21–23 months old female mice
were injected subcutaneously 5×/week for two weeks with either vehicle or PTH (40 μg/kg
BW) as described in materials and methods. Two days after the last injection, total RNA was
extracted from whole left tibia excluded epiphyses for ATF4 analysis by qPCR (A). (B)
Immunohistochemistry for ATF4 protein expression in vertebrae tissue and in osteoblast
cells lining on bone surface (arrow) (maganification, 400×). Representative image of
vertebrae from each treatment group and genotype are shown.
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Schematic model - The impaired bone anabolic effect of PTH in Fgf2 knockout mice is
associated with reduced ATF4 expression. Anabolic action of PTH on bone formation
requires FGF2 and FGF2 increases ATF4 expression and transcriptional activity in
osteoblasts. Moreover, ATF4 is a downstream target of PTH signaling in osteoblasts and
ATF4 is critical for osteoblasts differentiation. Therefore, attenuated ATF4 expression in
Fgf2−/− mice by PTH injection may contribute to reduced osteoblasts differentiation
characterized by decreased osteocalcin and type I collagen expression, which results in
impaired stimulation of bone formation by PTH.
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